James Pound
James Pound joined the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) in 2008. He has worked in a variety of roles within the MHRA and is an executive leader within the Agency with responsibility for our Innovation Accelerator (the home of our innovative pathways for medicines and medical devices), the clinical investigations and trials group and the standards and compliance function which includes our Medicines GXP compliance teams, British Pharmacopoeia and medical devices audit and compliance. James led the cross-Agency response to clinical trial assessment delays in 2023 which were successfully eliminated in Autumn 2023 with sustained performance by the Agency since then.
He holds an honours degree in Chemistry and has previously worked in a variety of roles in development and manufacturing in the pharmaceutical industry.
Sessions
-
Accelerating Access: Regulatory Support for Advanced Therapies in the UK28-Jan-2026Advanced Therapies Stage
-
Panel Discussion: How Do We Design, Execute and Adapt Clinical Trials for One-Time or Personalised Advanced Therapies?28-Jan-2026Advanced Therapies Stage